Company profile

Incorporated in
Fiscal year end
Former names
New Moon B.V.

MYL stock data



7 May 19
18 Jun 19
31 Dec 19


Company financial data Financial data

Quarter (USD) Mar 19 Dec 18 Sep 18 Jun 18
Revenue 2.5B 3.08B 2.86B 2.81B
Net income -25M 176.7M 37.5M
Diluted EPS -0.05 0.1 0.34 0.07
Net profit margin -1.00% 6.17% 1.34%
Operating income 24M 232.8M 338.2M 178.9M
Net change in cash -158.3M -61.1M 119M -37.2M
Cash on hand 229.8M 388.1M 449.2M 330.2M
Cost of revenue 1.69B 2.06B 1.82B 1.85B
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 11.43B 11.91B 11.08B 9.43B
Net income 480M 847.6M
Diluted EPS 0.68 1.3 0.92 1.7
Net profit margin 4.33% 8.99%
Operating income 905.6M 1.44B 699.2M 1.46B
Net change in cash 96M -706.7M -237.2M 1.01B
Cash on hand 388.1M 292.1M 998.8M 1.24B
Cost of revenue 7.43B 7.12B 6.38B 5.21B

Financial data from Mylan earnings reports

Financial report summary

Management Discussion
  • This Form 10-Q contains “forward-looking statements.” These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about Mylan’s future operations, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competition, and other expectations and targets for future periods. These may often be identified by the use of words such as “will,” “may,” “could,” “should,” “would,” “project,” “believe,” “anticipate,” “expect,” “plan,” “estimate,” “forecast,” “potential,” “pipeline,” “intend,” “continue,” “target,” “seek” and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: actions and decisions of healthcare and pharmaceutical regulators; failure to achieve expected or targeted future financial and operating performance and results; uncertainties regarding future demand, pricing and reimbursement for our products; any regulatory, legal, or other impediments to Mylan’s ability to bring new products to market, including, but not limited to, where Mylan uses its business judgment and decides to manufacture, market, and/or sell products, directly or through third parties, notwithstanding the fact that allegations of patent infringement(s) have not been finally resolved by the courts (i.e., an “at-risk launch”); success of clinical trials and Mylan’s ability to execute on new product opportunities; any changes in or difficulties with our manufacturing facilities, including with respect to our remediation and restructuring activities, supply chain or inventory or our ability to meet anticipated demand; the scope, timing, and outcome of any ongoing legal proceedings, including government investigations, and the impact of any such proceedings on our financial condition, results of operations, and/or cash flows; the ability to meet expectations regarding the accounting and tax treatments of acquisitions, including Mylan’s acquisition of Mylan Inc. and Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business (the “EPD Business”); changes in relevant tax and other laws, including but not limited to changes in the U.S. tax code and healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any significant breach of data security or data privacy or disruptions to our information technology systems; the ability to protect intellectual property and preserve intellectual property rights; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel; the impact of competition; identifying, acquiring, and integrating complementary or strategic acquisitions of other companies, products, or assets being more difficult, time-consuming or costly than anticipated; the possibility that Mylan may be unable to achieve expected synergies and operating efficiencies in connection with strategic acquisitions, strategic initiatives or restructuring programs within the expected time-frames or at all; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions and global exchange rates; and inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and related standards or on an adjusted basis. For more detailed information on the risks and uncertainties associated with Mylan’s business activities, see the risks described in the 2018 Form 10-K, and our other filings with the SEC. You can access Mylan’s filings with the SEC through the SEC website at or through our website, and Mylan strongly encourages you to do so. Mylan routinely posts information that may be important to investors on our website at, and we use this website address as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). The contents of our website are not incorporated by reference in this Form 10-Q and shall not be deemed “filed” under the Securities Exchange Act of 1934, as amended. Mylan undertakes no obligation to update any statements herein for revisions or changes after the filing date of this Form 10-Q other than as required by law.
  • Mylan is a global pharmaceutical company committed to setting new standards in healthcare and providing 7 billion people access to high quality medicine. We offer a growing portfolio of more than 7,500 products, including prescription generic, branded generic, brand-name drugs and over-the-counter (“OTC”) remedies. We market our products in more than 165 countries and territories. Every member of our approximately 35,000-strong global workforce is dedicated to delivering better health for a better world.
Content analysis ?
8th grade Avg
New words: AbbVie, abiraterone, adalimumab, Aspen, assignee, back, bear, belief, Biotech, BTG, canceled, choose, confident, detection, dose, erred, estate, estoppel, evolution, FKB, fluticasone, Framework, GUK, Hulio, Humira, identification, implicit, Importantly, impurity, inception, increasingly, ingestion, InhubTM, Interaction, Interbank, IPR, Janssen, largest, London, MYL, national, notified, Oncology, outlined, overlap, package, Pharmacare, pledged, point, pre, propionate, real, recommended, refund, repayment, ROU, salmeterol, SDNY, serialization, stemming, sustained, trace, Trademark, turn, UFJ, USP, valsartan, warning, WixelaTM, Zealand
Removed: AB, account, activate, addressing, admission, advocacy, albuterol, allocation, Alternatively, amitriptyline, analyzing, annually, API, application, arrangement, Article, assist, Assistance, assumed, attainment, BEAT, benazepril, bond, Book, brand, briefly, Bulletin, called, Cambrex, campaign, capitalization, capitalized, CIA, cited, Claire, classify, clomipramine, closure, cold, collected, commercially, concentration, conducted, consisted, consolidation, consultation, continuation, contracted, controlled, country, creating, critical, dated, de, decline, deductibility, deductible, deduction, defect, defending, Delaware, designed, determinable, determination, developer, device, Dey, digoxin, disaggregate, divalproex, domestic, educational, eligibility, eliminating, enactment, enjoin, entirety, Erosion, examined, exempt, expanded, faith, Famy, favorably, feedback, female, finalization, forma, formula, fourteen, fulfill, fulfillment, funded, GILTI, good, Gyma, handling, Homeland, Human, impaired, implementation, improve, inclusive, incomplete, indenture, independently, initiated, injunction, innovator, Inspector, institutional, Integrity, invoice, IV, Jai, Jr, jurisdiction, jury, large, largely, launched, lender, levothyroxine, limit, limiting, listed, lot, mandated, McCaskill, Meda, Meridian, modification, Momenta, Nefopam, NHS, noted, nursing, objective, obligate, offering, opening, opioid, opted, Orange, parent, percent, peremptory, policy, portray, positively, practice, pravastatin, preceding, prepare, pro, prompt, prospective, prospectively, provisional, publ, putting, qualified, ranking, reacquire, reacquisition, readily, recalled, recast, receipt, recognizing, reconcile, reconsideration, redeemable, redeemed, redemption, reimburse, reinvest, remeasure, remeasurement, remedy, remitted, rendered, repeal, replacing, requested, retrospectively, SAB, sector, select, Senate, Senator, sequenced, set, shipping, Shortly, shutdown, simplify, smaller, Social, soliciting, Specifically, spectrum, spread, statute, subtotal, successful, suit, sum, supersede, supplemented, surety, taxable, taxation, Technical, tentatively, Treasury, treat, uncertainty, underwritten, unexpired, unpaid, unrepatriated, untaxed, utilization, valid, varying, verdict, withholding, wrongdoing, Yeda